April 2017

Sawyer: Lineage plasticity in mPrCa - TP53/RB1 knockdown causes shift to base lineage gene exp '17 Science https://t.co/Z4hWJvB72J #AACR17

12:22pm April 2nd 2017 via Hootsuite

Sawyer: Not onto TP53 alterations in castration-resistant, mPrCa '15 Cell https://t.co/beuDMlNvJM #AACR17

12:20pm April 2nd 2017 via Hootsuite

Sawyer: GR expression is reversible; Enz +/- may drive GR expression; suggests 2-step model of GR regulation; H3K27me3 mark on prom #AACR17

12:15pm April 2nd 2017 via Hootsuite

Sawyer: Two mech - AR bypass, lineage plasticity. AR bypass is via exp of glucocorticoid recept GR '13 Cell https://t.co/PnM92UJEI1 #AACR17

12:12pm April 2nd 2017 via Hootsuite

Sawyer: For mPrCa - 1st-gen AR Rx, relaps AR over-expressed/ampl after Rx; enzalutamide Rx. Resist 2nd time 50% AR mut/amp #AACR17

12:10pm April 2nd 2017 via Hootsuite

Sawyer: Four TKI's now on the market, BCR-ABL. Reminds a sequential Rx may need combination approaches https://t.co/2FvHPsSu7K #AACR17

12:07pm April 2nd 2017 via Hootsuite

Charles Sawyer (Memorial Sloan NY) New twists on cancer drug resistance #AACR17

12:04pm April 2nd 2017 via Hootsuite

Vogelstein: Shows clip from movie Elysium, a Dx 'just like that'. But 50y ago, and MRI machine was at the same place. #AACR17

11:59am April 2nd 2017 via Hootsuite

Vogelstein: Same idea with saliva, and blood. 96% in saliva, larynx 52%. Combined >90% for larynx. #AACR17

11:57am April 2nd 2017 via Hootsuite

Vogelstein: Wang, Papadopoulus manuscript 2017: endometrial 93% detection n=224, Ovarian 43% n=182. Combined: Ov inc. to 71% #AACR17

11:56am April 2nd 2017 via Hootsuite

Vogelstein: Another idea - not only ctDNA but also released gDNA from the localized site. Isaac Kinde, Luis Diaz: use pap smears #AACR17

11:55am April 2nd 2017 via Hootsuite

Vogelstein: Work to be published later this year - combination blood test for pancreatic - >75% of Stage IA/IB. Lennon, Kinzler #AACR17

11:54am April 2nd 2017 via Hootsuite

Vogelstein: So liquid biopsies can use combination of mutations, markers: methylation, transcripts, proteins, metabolites. #AACR17

11:53am April 2nd 2017 via Hootsuite

Vogelstein: Prevention of 30% is 'why isn't it 100%?' Ideas to increase sensitivity of ctDNA - Rx mainstays are in combinations #AACR17

11:52am April 2nd 2017 via Hootsuite

Vogelstein: Perception of success of prevention vs success of Rx is 'dramatically different'. New Rx at 30% = miraculous. #AACR17

11:51am April 2nd 2017 via Hootsuite

Vogelstein: Onto liquid biopsies - for metastatic disease, 'works beautifully'. Problem is w/localized disease - 30-50% detection. #AACR17

11:50am April 2nd 2017 via Hootsuite

Vogelstein: First two, nothing can be done at present; the other two, chemoprevention, early detection. #AACR17

11:48am April 2nd 2017 via Hootsuite

Vogelstein: Random causes: quantum effects of base pairing, polymerase effects; hydrolytic deamination, also endogenous ROS #AACR17

11:47am April 2nd 2017 via Hootsuite

Vogelstein: Why impt? The first step in any war is to determine where the enemy is located. Primary prevention. #AACR17

11:45am April 2nd 2017 via Hootsuite

Vogelstein: Thus about 40% can be prevented; due to multiple dependencies of individual mutations. #AACR17

11:44am April 2nd 2017 via Hootsuite

Vogelstein: Environment, heredity. Now a third - last week https://t.co/npwJZHhelO random mutations. ~65% (etiology, not incidence) #AACR17

11:43am April 2nd 2017 via Hootsuite

Bert Vogelstein: #AACR17 MRD lays the foundation for a new type of adjuvant therapy trials '16 Science TM https://t.co/hk3EGTKnen

11:41am April 2nd 2017 via Hootsuite

Vogelstein: It takes years - perhaps decades - for mets to develop. Early det synergizes rather than competes w/new Rx #AACR17

11:40am April 2nd 2017 via Hootsuite

Vogelstein: Small amts of disease can be cured by chemotherapy. Micromets - close to 50% cure rate. With visible mets - close to 0 #AACR17

11:39am April 2nd 2017 via Hootsuite

Vogelstein: "Senior cancer scientist says "turn people into mice". Let's cut funding another 20%" (lazy journalist headline) #AACR17

11:38am April 2nd 2017 via Hootsuite

Vogelstein: A numbers game - mouse tumors are 1000-fold larger than humans. 'Turn humans into mice. Please don't tweet that!' #AACR17

11:37am April 2nd 2017 via Hootsuite

Vogelstein: "I am particularly good at curing mice... I'm not so good at curing people." Why - just arithmetic. #AACR17

11:36am April 2nd 2017 via Hootsuite

Vogelstein: Drug resistance: 100's to thousands of resistant cells already there, prior to Rx. In mice - situation different #AACR17

11:35am April 2nd 2017 via Hootsuite

Vogelstein: Two approaches are synergistic; shows famous Wagle vemurafenib photo '11 JCO https://t.co/5Mc4lez5Yx #AACR17

11:34am April 2nd 2017 via Hootsuite

Vogelstein: How to accomplish the next revolution: either new Rx, or (not as well recognized) new modes of prevention #AACR17

11:33am April 2nd 2017 via Hootsuite

Vogelstein: There is more to cancer than mutations: not all that have pneumococcus have pneumonia. If no pneumococcus, no pneumonia. #AACR17

11:32am April 2nd 2017 via Hootsuite

Vogelstein: There has been a revolution in cancer research - cancer results in the sequential accumulation of DNA alterations #AACR17

11:31am April 2nd 2017 via Hootsuite

Bert Vogelstein (Johns Hopkins, MD) Earlier detection as a key to lower cancer death rates #AACR17

11:30am April 2nd 2017 via Hootsuite

Caldas: TCR and neo-AG are significantly co-shared across metastasis (preliminary). #AACR17

11:28am April 2nd 2017 via Hootsuite

Caldas: Cluster samples based upon TCR repertoire, clustering depending on where the mets appear. Looked at phylogenetic trees #AACR17

11:27am April 2nd 2017 via Hootsuite

Caldas: TME can vary, genomic scars vary as well. #AACR17

11:23am April 2nd 2017 via Hootsuite

Caldas: Concludes - metastasis are generated, maintained and spread as communities of clones. Stem muts are freq sub-clonal #AACR17

11:23am April 2nd 2017 via Hootsuite

Caldas: A consistent 'genomic scar' in lethal br cancer - could be in resp to cytotoxic Rx. Analysis in stem vs clade vs private #AACR17

11:19am April 2nd 2017 via Hootsuite

Caldas: Onto lethal mBrCa - heavily pre-treated, often 6 to 9 lines of trtmt. Landscape of drivers: about 100 mutation drivers. #AACR17

11:14am April 2nd 2017 via Hootsuite

Caldas: Dynamic changes of TME and neoAG load can predict response to cytotoxic Rx. #AACR17

11:12am April 2nd 2017 via Hootsuite

Caldas: In tumors that are resistant - muts in CNAs using 'Superfrag' tool; immune TME via RNAseq shows recruitment of resist cells #AACR17

11:11am April 2nd 2017 via Hootsuite

Caldas: Looking at ITH, TME in serial biopsies for neo-adjuvant Rx in ER+, TNBC, HER2+. ER+ slightly higher in TP53 #AACR17

11:09am April 2nd 2017 via Hootsuite

Caldas: Difference is prominent lymphocytic infiltration. '15 Cell https://t.co/luBN6pNyyy TME #AACR17

11:07am April 2nd 2017 via Hootsuite

Caldas: Landscapes of early br ca 11 distinct genomic subtypes '16 Nature Comm https://t.co/O8KrE5MQJb ITH varies sig across types #AACR17

11:06am April 2nd 2017 via Hootsuite

Caldas: Cancer is a community of cells, as a community of clones. 3 unpublished stories: dynamics of ITH/TME in neoadjuvant Rx; #AACR17

11:04am April 2nd 2017 via Hootsuite

Carlos Caldas (Cancer Research UK Cambridge UK) Breast cancer intratumor heterogeneity landscapes: what, when and where #AACR17

11:02am April 2nd 2017 via Hootsuite

Belcher: (Comment: Remarkable progress on the materials sciences and its intersection to detection, novel detection platforms) #AACR17

11:02am April 2nd 2017 via Hootsuite

Belcher: Now can target human glioma targets, also T-cells in real-times for immunotherapy with other Ln-based materials #AACR17

11:00am April 2nd 2017 via Hootsuite

Belcher: Much smaller - from 980nm (wt) to 100nm (inho). Needed smaller carbon nanotubes; using DNA origami, self-assembling DNAs #AACR17

10:59am April 2nd 2017 via Hootsuite